Detalles de la búsqueda
1.
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522.
Ann Oncol
; 35(5): 429-436, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38369015
2.
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Breast Cancer Res
; 25(1): 103, 2023 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37653397
3.
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study.
Ann Oncol
; 34(7): 569-577, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37179020
4.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Ann Oncol
; 34(8): 660-669, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37201751
5.
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
Ann Oncol
; 33(11): 1149-1158, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35961599
6.
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Ann Oncol
; 32(8): 1015-1024, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34102253
7.
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Ann Oncol
; 32(12): 1590-1596, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34520831
8.
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapyâ.
Ann Oncol
; 32(4): 500-511, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33418062
9.
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
Ann Oncol
; 32(1): 49-57, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33098995
10.
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Ann Oncol
; 32(12): 1571-1581, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34656740
11.
Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol
; 163(3): 465-472, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34642026
12.
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
Ann Oncol
; 31(9): 1216-1222, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32461104
13.
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Ann Oncol
; 30(8): 1279-1288, 2019 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31095287
14.
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial.
Ann Oncol
; 29(8): 1777-1783, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29893791
15.
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Ann Oncol
; 29(12): 2341-2347, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30335131
16.
[TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes]. / TILGen-Studie Immunologische Angriffspunkte bei Patientinnen mit Brustkrebs : Einfluss der tumorinfiltrierenden Lymphozyten.
Pathologe
; 39(Suppl 2): 236-240, 2018 Dec.
Artículo
en Alemán
| MEDLINE | ID: mdl-30406831
17.
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].
Ann Oncol
; 33(7): 743-744, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35595658
18.
Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study.
Breast Cancer Res Treat
; 162(3): 479-488, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28176175
19.
Prenatal and adult androgen activities in alcohol dependence.
Acta Psychiatr Scand
; 136(1): 96-107, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28383757
20.
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
Ann Oncol
; 32(10): 1307, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34412950